Severe hypertriglyceridaemia associated with human immunodeficiency virus and highly active antiretroviral therapy.
We report two cases of severe hypertriglyceridaemia associated with human immunodeficiency virus infection and highly active antiretroviral therapy (HAART). The first patient, a 39-year-old man, developed moderate hypertriglyceridaemia (5.88 mmol/L) and hypercholesterolaemia (7.0 mmol/L) after 8 months of HAART. When his therapy was altered, triglyceride and cholesterol concentrations increased further to 15.9 and 10.9 mmol/L, respectively, after 6 weeks. The second patient, a 31-year-old man, presented with triglyceride and cholesterol concentrations of 16.2 and 5.7 mmol/L, respectively, following an 8-year history of HAART. Therapy was changed, but 1 month later the triglyceride concentration had increased to 39.4 mmol/L and the cholesterol concentration to 12.1 mmol/L. Both patients were managed by a change in HAART and the introduction of a fibric acid derivative. Although neither patient displayed any clinical symptoms associated with hypertriglyceridaemia, it is important to recognize such cases because of the associated risk of pancreatitis and coronary disease.
Department of Clinical Biochemistry and Immunology, Leeds General Infirmary, Leeds LS1 3EX, UK. RachelC@pathology.leeds.ac.uk
R S
RS
Carling
R
R
Hextall
P A
PA
DeSilva
J H
JH
Barth
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D006678:HIV / Q000502:physiology*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D015228:Hypertriglyceridemia / Q000150:complications* / Q000821:virology*; D008297:Male; D014280:Triglycerides / Q000097:blood
D019380:Anti-HIV Agents; D001786:Blood Glucose; D014280:Triglycerides; D002784:Cholesterol